Replimune Group, Inc. (FRA:7R8)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.28B +238.0% |
| Revenue (ttm) | n/a |
| Net Income | -259.98M |
| EPS | -2.76 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 13.25 |
| Previous Close | 12.24 |
| Day's Range | 13.21 - 13.25 |
| 52-Week Range | 1.43 - 13.47 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Replimune Group
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an an... [Read more]
News
Replimune price target raised to $21 from $20 at JPMorgan
JPMorgan raised the firm’s price target on Replimune (REPL) to $21 from $20 and keeps an Overweight rating on the shares. The firm says key opinion leader commentary supports a…
REPL Stockholders Have Rights – If You Lost Money Investing in Replimune Group, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ann...
Replimune files automatic mixed securities shelf
16:53 EDT Replimune (REPL) files automatic mixed securities shelf
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends ca...
Replimune Group Earnings release: Q1 2027
Replimune Group released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Replimune Group Quarterly report: Q1 2027
Replimune Group has published its Q1 2027 quarterly earnings report on August 14, 2026.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated...
Replimune Announces Pricing of $150 Million Underwritten Offering
BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, to...
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.
Replimune price target raised to $20 from $16 at BMO Capital
BMO Capital raised the firm’s price target on Replimune (REPL) to $20 from $16 and keeps an Outperform rating on the shares. Replimune received a key regulatory win with Tudriqev…
Wedbush upgrades Replimune to Outperform following FDA decision
As previously reported, Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up from $12. The firm notes the Food and Drug Administration granted accelerated…
Replimune upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up from $12.
Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma
Replimune (REPL) announced that the FDA has granted accelerated approval for Tudriqev, previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanc...
Replimune Group Transcript: FDA announcement
FDA granted accelerated approval to TUDRIQEV for advanced melanoma after PD-1 progression, based on a 24.2% response rate in a real-world population. The therapy is well-tolerated, with broad label coverage and a phased commercial rollout planned, supported by robust patient and provider programs.
Replimune Group Press release: FDA announcement
Replimune Group issued a press release on August 6, 2026, disclosing material business information to investors.
Replimune Group Slides: FDA announcement
Replimune Group has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
US FDA approves Replimune's skin cancer drug
The U.S. Food and Drug Administration has approved Replimune's drug for a difficult-to-treat form of skin cancer, the company said on Thursday, giving the biotech firm its first marketed product af...
FDA Approves Replimune's Melanoma Drug On Third Attempt
The agency had turned down two earlier applications over clinical data-quality concerns.
Replimune upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Replimune (REPL) to Outperform from Market Perform with a price target of $17, up from $11. The firm has “high conviction” the FDA will grant RP-1 plus nivolumab…
Why Is Replimune (REPL) Stock Up Today?
Replimune stock rallied on Friday thanks to an FDA update that acted as a catalyst for analyst upgrades.
Piper upgrades Replimune to Overweight on better odds of RP1 approval
As previously reported, Piper Sandler analyst Allison Bratzel upgraded Replimune (REPL) to Overweight from Neutral with a price target of $14, up from $9. The postive FDA panel vote supporting…
Replimune upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Replimune (REPL) to Overweight from Neutral with a $14 price target
This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment
Replimune stock soars after a FDA advisory committee votes that the company's study on its skin cancer treatment is ‘clinically meaningful.'
Replimune price target raised to $12 from $9 at Wedbush
Wedbush raised the firm’s price target on Replimune (REPL) to $12 from $9 and keeps a Neutral rating on the shares. The firm notes the FDA convened an Advisory Committee…